DB ups Roche to 'buy' on positive oncology survey
** Deutsche Bank DBKGn.DE upgrades Swiss healthcare company Roche ROPC.S to "buy" from "hold" driven by positive physician feedback from a proprietary oncology survey
** DB notes that physician sentiment on breast cancer treatment giredestrant has leaned positive for some time with implications resonating in the near term
** Analysts at the bank admit being "late to a consensus trade" but argue they see little obvious reason for a better entry point into the stock anytime soon
** They add that immediate pipeline risks have diminished while modest expectations for fenebrutinib mean multiple sclerosis data offer limited concern
** Out of 24 analysts that cover the stock, 12 rate the it "strong buy" or "buy", 10 rate it "hold" and 2 rate it "strong sell" or "sell" - LSEG data